Expressions of Endocan in Patients with Meningiomas and Gliomas

Atukeren, Pınar; Kunbaz, Ahmad; Türk, Okan; Kemerdere, Rahşan; Ulu, Mustafa Onur; İnanır, Nursel Türkmen; Tanrıverdi, Taner

doi:10.1155/2016/7157039

Cited by 17 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that the mean level of endocan has a significant incline from the control group to the malignant tumor groups although the meningioma (benign) had the lowest mean level, and the high-grade glioma (most malignant) group had the highest mean level. They also showed that incline expression was significantly correlated with the degree of malignancy, which means that with increasing the degree of malignancy, the endocan expression also increased [26]. In another study, Maurage and colleagues investigated endocan expression in brain tumors.…”

Section: Discussionmentioning

confidence: 98%

Endocan serum levels in patients with low- and high-grade meningiomas: does this biomarker have an indicative role?

Fattahi

Sedaghat

Malekzadeh

et al. 2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Meningiomas are one of the most common tumors of the brain and central nervous system. The key role of endocan in predicting tumor growth and prognosis has been shown for several types of cancers; however, this role in meningiomas has not been evaluated. In the current study, we investigated the relationship between endocan serum levels with low- and high-grade meningiomas. Results The serum level of endocan in the group with meningiomas was 283.34 (242.09-358.70) pg/ml and in the control group was 250.29 (207.56-329.71) pg/ml respectively (P = 0.172). Afterwards, patients were divided into three different groups (grades I, II, and III) and compared to the control. The level of endocan in the group with grade I of meningioma showed no significant difference compared to control individuals (P = 0.86). When patients with grade II and grade III compared with the control group, endocan serum levels were statistically significant (P = 0.002, P < 0.001 respectively). Moreover, our findings showed that the different grades of meningiomas were statistically significant compared to each other (P < 0.001) regarding endocan serum levels, meaning that the higher the grade, the higher the endocan serum levels. Conclusion Our findings revealed that higher grades of meningioma had higher endocan serum levels, however, the role of endocan in pathogenesis or progression of this type of tumor requiring further exclusively assessment.

show abstract

Section: Discussionmentioning

confidence: 98%

Endocan serum levels in patients with low- and high-grade meningiomas: does this biomarker have an indicative role?

Fattahi

Sedaghat

Malekzadeh

et al. 2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

show abstract

“…According to the published work on meningioma and glioma, endocan expression showed a steady incline from the controls to the most malignant form of the tumor groups. The authors suggested a positive correlation between the endocan expression level and the degree of malignancy (38). These findings may confirm the role of endocan in cancer cell differentiation.…”

Section: Discussionmentioning

confidence: 54%

Endocan Expression Profile in Different Grades of Oral Squamous Cell Carcinoma

Irani

Amiri

2019

Int J Cancer Manag

View full text Add to dashboard Cite

Background: Oral cancer is one of the most prevalent malignancies and presents increasing incidence and mortality trends in the world, with a mortality rate of 14.33%. Oral squamous cell carcinoma (OSCC) constitutes 90% of all malignancies in the oral cavity. In spite of new therapeutic strategies, the risk of metastasis and mortality rate is still very high. Methods: A total of 54 samples (18 samples of each grade) were collected from the archives of the Pathology Department of Be'sat Educational Hospital, Hamadan, Iran from 2000 to 2017. The specimens were processed for immunohistochemistry (IHC) analysis. Besides, the samples were stained with Periodic Acid-Schiff (PAS) method for vasculogenic mimicry (VM) detection. Results: The chi-square test showed statistically significant differences between the expression level of endocan and lesion grade in the research groups (P = 0.025), lesion grade and VM formation (P = 0.001), and tumor grade and microvessel density (MVD) count (P = 0.000). Conclusions: The results suggest that endocan mediates tumor progression possibly via a few mechanisms such as cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT), and VM formation. Further studies are required to reveal the mechanisms, by which the endocan acts as an oncogene. In addition, endocan could be considered as one of the tumor markers and a possible new target for cancer therapy.

show abstract

“…Endocan, the endothelial cell speci c molecule-1 (ESM-1), was demonstrated to be associated with angiogenesis and tumor growth in lung, kidney and liver among other cancers (10)(11)(12). Moreover, endocan expression was correlated with high grade gliomas (13,14). It has been proposed as a neovascularization marker, being stimulated by two other important angiogenic factors VEGF and broblast growth factor (FGF2) (10,13), and, importantly, it is involved in the switch from dormant to fast growing and angiogenic tumors (15).…”

Section: Read Full License Introductionmentioning

confidence: 99%

Endocan, VEGF, FGF2 and PDGF Expression in Pituitary Tumors. A Precise Angiogenic Marker Relationship in the Context of Tumor Invasiveness

Tao

Perrone

Demarchi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Pituitary adenomas can become invasive and aggressive, and in turn produce tumor recurrence. Endocan or endothelial cell specific molecule-1 (ESM1) has been associated with angiogenesis and tumor growth in gliomas, and lung, kidney, liver among other cancers, but there is a scarcity of information regarding its role in pituitary adenomas. In the search for biomarkers of tumor behavior our objective was to determine the relationship between endocan (ESM1) mRNA expression and cavernous sinus invasion, and its association with gene expression of VEGF, FGF2 and PDGF angiogenic factors in human pituitary adenomas.Methods: ESM1, VEGF, FGF2 and PDGF expression was determined by qRT-PCR in 28 pituitary tumor samples and tumor invasion was determined by the Knosp grade classification. Results were associated with clinical data. Results: We found that ESM1 was expressed in 75% of the tumors. FGF2 expression was higher in ESM1-positive compared to ESM1-negative tumors, and a significant negative correlation in the expression of FGF2 and PDGF was found. Although ESM1 expression did not show any differences in invasive and non-invasive tumors, a positive correlation between ESM1 and Knosp grade was reached when grade 0-3 tumors were considered, suggesting its participation in the initial periods of tumor invasion. Finally, no difference in ESM1 expression was found between functioning and non-functioning adenomas, or patients age. Conclusions: Our study points to a precise pattern of angiogenic factor expression in pituitary tumors, and its relation to invasive behavior, which should be considered in the tailoring of drug treatments for aggressive and resistant pituitary adenomas.

show abstract

Expressions of Endocan in Patients with Meningiomas and Gliomas

Cited by 17 publications

References 15 publications

Endocan serum levels in patients with low- and high-grade meningiomas: does this biomarker have an indicative role?

Endocan serum levels in patients with low- and high-grade meningiomas: does this biomarker have an indicative role?

Endocan Expression Profile in Different Grades of Oral Squamous Cell Carcinoma

Endocan, VEGF, FGF2 and PDGF Expression in Pituitary Tumors. A Precise Angiogenic Marker Relationship in the Context of Tumor Invasiveness

Contact Info

Product

Resources

About